Cargando…

Proteomic analysis of tumor necrosis factor-α resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype

INTRODUCTION: Despite intensive study of the mechanisms of chemotherapeutic drug resistance in human breast cancer, few reports have systematically investigated the mechanisms that underlie resistance to the chemotherapy-sensitizing agent tumor necrosis factor (TNF)-α. Additionally, the relationship...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Changhua, Nitschke, Ashley M, Xiong, Wei, Zhang, Qiang, Tang, Yan, Bloch, Michael, Elliott, Steven, Zhu, Yun, Bazzone, Lindsey, Yu, David, Weldon, Christopher B, Schiff, Rachel, McLachlan, John A, Beckman, Barbara S, Wiese, Thomas E, Nephew, Kenneth P, Shan, Bin, Burow, Matthew E, Wang, Guangdi
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2656902/
https://www.ncbi.nlm.nih.gov/pubmed/19087274
http://dx.doi.org/10.1186/bcr2210
_version_ 1782165541354471424
author Zhou, Changhua
Nitschke, Ashley M
Xiong, Wei
Zhang, Qiang
Tang, Yan
Bloch, Michael
Elliott, Steven
Zhu, Yun
Bazzone, Lindsey
Yu, David
Weldon, Christopher B
Schiff, Rachel
McLachlan, John A
Beckman, Barbara S
Wiese, Thomas E
Nephew, Kenneth P
Shan, Bin
Burow, Matthew E
Wang, Guangdi
author_facet Zhou, Changhua
Nitschke, Ashley M
Xiong, Wei
Zhang, Qiang
Tang, Yan
Bloch, Michael
Elliott, Steven
Zhu, Yun
Bazzone, Lindsey
Yu, David
Weldon, Christopher B
Schiff, Rachel
McLachlan, John A
Beckman, Barbara S
Wiese, Thomas E
Nephew, Kenneth P
Shan, Bin
Burow, Matthew E
Wang, Guangdi
author_sort Zhou, Changhua
collection PubMed
description INTRODUCTION: Despite intensive study of the mechanisms of chemotherapeutic drug resistance in human breast cancer, few reports have systematically investigated the mechanisms that underlie resistance to the chemotherapy-sensitizing agent tumor necrosis factor (TNF)-α. Additionally, the relationship between TNF-α resistance mediated by MEK5/Erk5 signaling and epithelial-mesenchymal transition (EMT), a process associated with promotion of invasion, metastasis, and recurrence in breast cancer, has not previously been investigated. METHODS: To compare differences in the proteome of the TNF-α resistant MCF-7 breast cancer cell line MCF-7-MEK5 (in which TNF-α resistance is mediated by MEK5/Erk5 signaling) and its parental TNF-a sensitive MCF-7 cell line MCF-7-VEC, two-dimensional gel electrophoresis and high performance capillary liquid chromatography coupled with tandem mass spectrometry approaches were used. Differential protein expression was verified at the transcriptional level using RT-PCR assays. An EMT phenotype was confirmed using immunofluorescence staining and gene expression analyses. A short hairpin RNA strategy targeting Erk5 was utilized to investigate the requirement for the MEK/Erk5 pathway in EMT. RESULTS: Proteomic analyses and PCR assays were used to identify and confirm differential expression of proteins. In MCF-7-MEK5 versus MCF-7-VEC cells, vimentin (VIM), glutathione-S-transferase P (GSTP1), and creatine kinase B-type (CKB) were upregulated, and keratin 8 (KRT8), keratin 19 (KRT19) and glutathione-S-transferase Mu 3 (GSTM3) were downregulated. Morphology and immunofluorescence staining for E-cadherin and vimentin revealed an EMT phenotype in the MCF-7-MEK5 cells. Furthermore, EMT regulatory genes SNAI2 (slug), ZEB1 (δ-EF1), and N-cadherin (CDH2) were upregulated, whereas E-cadherin (CDH1) was downregulated in MCF-7-MEK5 cells versus MCF-7-VEC cells. RNA interference targeting of Erk5 reversed MEK5-mediated EMT gene expression. CONCLUSIONS: This study demonstrates that MEK5 over-expression promotes a TNF-α resistance phenotype associated with distinct proteomic changes (upregulation of VIM/vim, GSTP1/gstp1, and CKB/ckb; and downregulation of KRT8/krt8, KRT19/krt19, and GSTM3/gstm3). We further demonstrate that MEK5-mediated progression to an EMT phenotype is dependent upon intact Erk5 and associated with upregulation of SNAI2 and ZEB1 expression.
format Text
id pubmed-2656902
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-26569022009-03-17 Proteomic analysis of tumor necrosis factor-α resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype Zhou, Changhua Nitschke, Ashley M Xiong, Wei Zhang, Qiang Tang, Yan Bloch, Michael Elliott, Steven Zhu, Yun Bazzone, Lindsey Yu, David Weldon, Christopher B Schiff, Rachel McLachlan, John A Beckman, Barbara S Wiese, Thomas E Nephew, Kenneth P Shan, Bin Burow, Matthew E Wang, Guangdi Breast Cancer Res Research Article INTRODUCTION: Despite intensive study of the mechanisms of chemotherapeutic drug resistance in human breast cancer, few reports have systematically investigated the mechanisms that underlie resistance to the chemotherapy-sensitizing agent tumor necrosis factor (TNF)-α. Additionally, the relationship between TNF-α resistance mediated by MEK5/Erk5 signaling and epithelial-mesenchymal transition (EMT), a process associated with promotion of invasion, metastasis, and recurrence in breast cancer, has not previously been investigated. METHODS: To compare differences in the proteome of the TNF-α resistant MCF-7 breast cancer cell line MCF-7-MEK5 (in which TNF-α resistance is mediated by MEK5/Erk5 signaling) and its parental TNF-a sensitive MCF-7 cell line MCF-7-VEC, two-dimensional gel electrophoresis and high performance capillary liquid chromatography coupled with tandem mass spectrometry approaches were used. Differential protein expression was verified at the transcriptional level using RT-PCR assays. An EMT phenotype was confirmed using immunofluorescence staining and gene expression analyses. A short hairpin RNA strategy targeting Erk5 was utilized to investigate the requirement for the MEK/Erk5 pathway in EMT. RESULTS: Proteomic analyses and PCR assays were used to identify and confirm differential expression of proteins. In MCF-7-MEK5 versus MCF-7-VEC cells, vimentin (VIM), glutathione-S-transferase P (GSTP1), and creatine kinase B-type (CKB) were upregulated, and keratin 8 (KRT8), keratin 19 (KRT19) and glutathione-S-transferase Mu 3 (GSTM3) were downregulated. Morphology and immunofluorescence staining for E-cadherin and vimentin revealed an EMT phenotype in the MCF-7-MEK5 cells. Furthermore, EMT regulatory genes SNAI2 (slug), ZEB1 (δ-EF1), and N-cadherin (CDH2) were upregulated, whereas E-cadherin (CDH1) was downregulated in MCF-7-MEK5 cells versus MCF-7-VEC cells. RNA interference targeting of Erk5 reversed MEK5-mediated EMT gene expression. CONCLUSIONS: This study demonstrates that MEK5 over-expression promotes a TNF-α resistance phenotype associated with distinct proteomic changes (upregulation of VIM/vim, GSTP1/gstp1, and CKB/ckb; and downregulation of KRT8/krt8, KRT19/krt19, and GSTM3/gstm3). We further demonstrate that MEK5-mediated progression to an EMT phenotype is dependent upon intact Erk5 and associated with upregulation of SNAI2 and ZEB1 expression. BioMed Central 2008 2008-12-16 /pmc/articles/PMC2656902/ /pubmed/19087274 http://dx.doi.org/10.1186/bcr2210 Text en Copyright © 2008 Zhou et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Zhou, Changhua
Nitschke, Ashley M
Xiong, Wei
Zhang, Qiang
Tang, Yan
Bloch, Michael
Elliott, Steven
Zhu, Yun
Bazzone, Lindsey
Yu, David
Weldon, Christopher B
Schiff, Rachel
McLachlan, John A
Beckman, Barbara S
Wiese, Thomas E
Nephew, Kenneth P
Shan, Bin
Burow, Matthew E
Wang, Guangdi
Proteomic analysis of tumor necrosis factor-α resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype
title Proteomic analysis of tumor necrosis factor-α resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype
title_full Proteomic analysis of tumor necrosis factor-α resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype
title_fullStr Proteomic analysis of tumor necrosis factor-α resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype
title_full_unstemmed Proteomic analysis of tumor necrosis factor-α resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype
title_short Proteomic analysis of tumor necrosis factor-α resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype
title_sort proteomic analysis of tumor necrosis factor-α resistant human breast cancer cells reveals a mek5/erk5-mediated epithelial-mesenchymal transition phenotype
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2656902/
https://www.ncbi.nlm.nih.gov/pubmed/19087274
http://dx.doi.org/10.1186/bcr2210
work_keys_str_mv AT zhouchanghua proteomicanalysisoftumornecrosisfactoraresistanthumanbreastcancercellsrevealsamek5erk5mediatedepithelialmesenchymaltransitionphenotype
AT nitschkeashleym proteomicanalysisoftumornecrosisfactoraresistanthumanbreastcancercellsrevealsamek5erk5mediatedepithelialmesenchymaltransitionphenotype
AT xiongwei proteomicanalysisoftumornecrosisfactoraresistanthumanbreastcancercellsrevealsamek5erk5mediatedepithelialmesenchymaltransitionphenotype
AT zhangqiang proteomicanalysisoftumornecrosisfactoraresistanthumanbreastcancercellsrevealsamek5erk5mediatedepithelialmesenchymaltransitionphenotype
AT tangyan proteomicanalysisoftumornecrosisfactoraresistanthumanbreastcancercellsrevealsamek5erk5mediatedepithelialmesenchymaltransitionphenotype
AT blochmichael proteomicanalysisoftumornecrosisfactoraresistanthumanbreastcancercellsrevealsamek5erk5mediatedepithelialmesenchymaltransitionphenotype
AT elliottsteven proteomicanalysisoftumornecrosisfactoraresistanthumanbreastcancercellsrevealsamek5erk5mediatedepithelialmesenchymaltransitionphenotype
AT zhuyun proteomicanalysisoftumornecrosisfactoraresistanthumanbreastcancercellsrevealsamek5erk5mediatedepithelialmesenchymaltransitionphenotype
AT bazzonelindsey proteomicanalysisoftumornecrosisfactoraresistanthumanbreastcancercellsrevealsamek5erk5mediatedepithelialmesenchymaltransitionphenotype
AT yudavid proteomicanalysisoftumornecrosisfactoraresistanthumanbreastcancercellsrevealsamek5erk5mediatedepithelialmesenchymaltransitionphenotype
AT weldonchristopherb proteomicanalysisoftumornecrosisfactoraresistanthumanbreastcancercellsrevealsamek5erk5mediatedepithelialmesenchymaltransitionphenotype
AT schiffrachel proteomicanalysisoftumornecrosisfactoraresistanthumanbreastcancercellsrevealsamek5erk5mediatedepithelialmesenchymaltransitionphenotype
AT mclachlanjohna proteomicanalysisoftumornecrosisfactoraresistanthumanbreastcancercellsrevealsamek5erk5mediatedepithelialmesenchymaltransitionphenotype
AT beckmanbarbaras proteomicanalysisoftumornecrosisfactoraresistanthumanbreastcancercellsrevealsamek5erk5mediatedepithelialmesenchymaltransitionphenotype
AT wiesethomase proteomicanalysisoftumornecrosisfactoraresistanthumanbreastcancercellsrevealsamek5erk5mediatedepithelialmesenchymaltransitionphenotype
AT nephewkennethp proteomicanalysisoftumornecrosisfactoraresistanthumanbreastcancercellsrevealsamek5erk5mediatedepithelialmesenchymaltransitionphenotype
AT shanbin proteomicanalysisoftumornecrosisfactoraresistanthumanbreastcancercellsrevealsamek5erk5mediatedepithelialmesenchymaltransitionphenotype
AT burowmatthewe proteomicanalysisoftumornecrosisfactoraresistanthumanbreastcancercellsrevealsamek5erk5mediatedepithelialmesenchymaltransitionphenotype
AT wangguangdi proteomicanalysisoftumornecrosisfactoraresistanthumanbreastcancercellsrevealsamek5erk5mediatedepithelialmesenchymaltransitionphenotype